Ligand Pharmaceuticals Announces Expansion of Global License and Supply Agreements With SAGE Therapeutics

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in connection with expanding its global license and supply agreements with SAGE Therapeutics. The agreement now covers the use of Captisol in the development and commercialization of SAGE-689.

Sage Therapeutics is a clinical-stage biopharmaceutical company that develops medicines for central nervous system disorders. Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Read the press release.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.